Article
Targeting Mdmx to treat breast cancers with wild-type p53.
Cell death & disease - 16 Jul 2015
Haupt S, Buckley D, Pang J-M B, Panimaya J, Paul P J, Gamell C, Takano E A, Lee Y Ying, Hiddingh S, Rogers T-M, Teunisse A F A S, Herold M J, Marine J-C, Fox S B, Jochemsen A, Haupt Y
Abstract excerpt
The function of the tumor suppressor p53 is universally compromised in cancers. It is the most frequently mutated gene in human cancers (reviewed). In cases where p53 is not mutated, alternative regulatory pathways inactivate its tumor suppressive functions. This is primarily achieved through elevation in the expression of the key inhibitors of p53: Mdm2 or Mdmx (also called Mdm4) (reviewed). In breast cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.